Aptabio Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Yongin Korea, Republic of (2009)

Organization Overview

First Clinical Trial
2018
NCT03694041
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Aptabio Therapeutics, Inc.